Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2017

04.02.2017 | Original Article

Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience

verfasst von: Tarun Rai, Bikash Narayan Choudhury, Saurabh Kedia, Sawan Bopanna, Pratap Mouli Venigalla, Sushil Kumar Garg, Vikas Singla, Govind Makharia, Vineet Ahuja

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Long-term outcome and natural history of steroid response in adult ulcerative colitis patients based on short-term response is largely unknown.

Aim

To evaluate whether short-term clinical response at 30  days after steroid initiation for moderate to severe disease can predict long-term outcome.

Methods

This prospective observational study recruited 161 patients who received oral/intravenous steroid therapy at our institution from April 2005 to July 2009. Short-term response at 30 days and long-term response at the end of first and third years were measured. Risk factors for long-term outcome at 1 and 3 years were analyzed by multivariate regression model.

Results

At the end of 30 days, 90 patients (55.9%) had complete response, 47 (29.2%) partial response, and 24 (14.9%) did not respond at all. At the end of first year, 53/90 (60%) complete responders (at 30 days) maintained steroid-free remission when compared to 17/71 (23.9%, p < 0.001) partial/no responders. Similar result was observed at the end of third year (74.7 vs 55.1%, p = 0.017). On multivariable analysis, short-term outcome at 30 days was a predictor of outcome at the end of one year (RR 4.1, 95% CI 2.2–8.5) and 3 years (RR 2.1, 95% CI 1.02–4.5).

Conclusions

Short-term response to steroids is a strong predictor of long-term outcome at 1 and 3 years in active ulcerative colitis patients.
Literatur
1.
Zurück zum Zitat Loftus EV Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–343.CrossRefPubMedPubMedCentral Loftus EV Jr., Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940–1993: incidence, prevalence, and survival. Gut. 2000;46:336–343.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Loftus CG, Loftus EV Jr., Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.CrossRefPubMed Loftus CG, Loftus EV Jr., Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.CrossRefPubMed
3.
Zurück zum Zitat Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103:1998–2006.CrossRefPubMed Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103:1998–2006.CrossRefPubMed
4.
Zurück zum Zitat Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the united states. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the united states. Clin Gastroenterol Hepatol. 2007;5:1424–1429.CrossRefPubMed
5.
Zurück zum Zitat Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in Northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol. 2006;18:601–606.CrossRefPubMed Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in Northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol. 2006;18:601–606.CrossRefPubMed
6.
7.
Zurück zum Zitat Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.CrossRefPubMed Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.CrossRefPubMed
8.
Zurück zum Zitat Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573–583.CrossRefPubMed Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573–583.CrossRefPubMed
10.
Zurück zum Zitat Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–1070.CrossRefPubMed Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067–1070.CrossRefPubMed
11.
Zurück zum Zitat Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978;2:1086–1088.CrossRefPubMed Truelove SC, Willoughby CP, Lee EG, Kettlewell MG. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 1978;2:1086–1088.CrossRefPubMed
12.
Zurück zum Zitat Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362.CrossRefPubMedPubMedCentral Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut. 1994;35:360–362.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963–2969.CrossRefPubMed Khan N, Abbas A, Williamson A, Balart L. Prevalence of corticosteroids use and disease course after initial steroid exposure in ulcerative colitis. Dig Dis Sci. 2013;58:2963–2969.CrossRefPubMed
16.
Zurück zum Zitat Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831–835.CrossRefPubMed Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol. 1998;10:831–835.CrossRefPubMed
17.
Zurück zum Zitat Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.CrossRefPubMed Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282–2291.CrossRefPubMed
18.
Zurück zum Zitat Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease—a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374–381.CrossRefPubMed Khan NH, Almukhtar RM, Cole EB, Abbas AM. Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease—a nationwide study of 1035 patients. Aliment Pharmacol Ther. 2014;40:374–381.CrossRefPubMed
19.
Zurück zum Zitat Garcia-Planella E, Manosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44:206–210.CrossRefPubMed Garcia-Planella E, Manosa M, Van Domselaar M, et al. Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. Dig Liver Dis. 2012;44:206–210.CrossRefPubMed
20.
Zurück zum Zitat Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114–1122.CrossRefPubMed Yoon JY, Cheon JH, Park JJ, Hong SP, Kim TI, Kim WH. Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. J Gastroenterol Hepatol. 2011;26:1114–1122.CrossRefPubMed
21.
Zurück zum Zitat Jeon HH, Lee HJ, Jang HW, et al. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol. 2013;19:265–273.CrossRefPubMedPubMedCentral Jeon HH, Lee HJ, Jang HW, et al. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol. 2013;19:265–273.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Chow DK, Sung JJ, Tsoi KK, et al. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a chinese cohort study. Aliment Pharmacol Ther. 2009;29:843–854.CrossRefPubMed Chow DK, Sung JJ, Tsoi KK, et al. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a chinese cohort study. Aliment Pharmacol Ther. 2009;29:843–854.CrossRefPubMed
24.
Zurück zum Zitat Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005;19:5–36.CrossRef
25.
Zurück zum Zitat Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.CrossRefPubMed Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 1: definitions and diagnosis. J Crohns Colitis. 2012;6:965–990.CrossRefPubMed
26.
Zurück zum Zitat Faubion WA Jr., Loftus EV Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.CrossRefPubMed Faubion WA Jr., Loftus EV Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255–260.CrossRefPubMed
27.
Zurück zum Zitat Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.CrossRefPubMed Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319–330.CrossRefPubMed
28.
Zurück zum Zitat Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in oxford: the 1992–1993 cohort. Inflamm Bowel Dis. 2009;15:823–828.CrossRefPubMed Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in oxford: the 1992–1993 cohort. Inflamm Bowel Dis. 2009;15:823–828.CrossRefPubMed
29.
Zurück zum Zitat Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada JR. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev Esp Enferm Dig. 2004;96:539–547.CrossRefPubMed Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada JR. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev Esp Enferm Dig. 2004;96:539–547.CrossRefPubMed
30.
Zurück zum Zitat Molnar T, Farkas K, Nyari T, Szepes Z, Nagy F, Wittmann T. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis. 2011;20:359–363.PubMed Molnar T, Farkas K, Nyari T, Szepes Z, Nagy F, Wittmann T. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis. 2011;20:359–363.PubMed
31.
Zurück zum Zitat Ahuja V, Tandon RK. Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol. 2012;31:294–296.CrossRefPubMed Ahuja V, Tandon RK. Inflammatory bowel disease: the Indian augury. Indian J Gastroenterol. 2012;31:294–296.CrossRefPubMed
32.
Zurück zum Zitat Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res. 2016;14:218–223.CrossRefPubMedPubMedCentral Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res. 2016;14:218–223.CrossRefPubMedPubMedCentral
Metadaten
Titel
Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience
verfasst von
Tarun Rai
Bikash Narayan Choudhury
Saurabh Kedia
Sawan Bopanna
Pratap Mouli Venigalla
Sushil Kumar Garg
Vikas Singla
Govind Makharia
Vineet Ahuja
Publikationsdatum
04.02.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2017
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4450-0

Weitere Artikel der Ausgabe 4/2017

Digestive Diseases and Sciences 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.